Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00198432
Status:
COMPLETED
Last Update Posted:
2016-03-10
First Post:
2005-09-13
Brief Title:
Chemoradiotherapy of NSCLC Stage IIIB
Sponsor:
Intergroupe Francophone de Cancerologie Thoracique
Organization:
Intergroupe Francophone de Cancerologie Thoracique
Study Overview
Official Title:
Randomized Phase II Study Evaluating an Induction Chemotherapy Followed by a Concomitant Chemoradiotherapy and a Concomitant Chemoradiotherapy Followed by a Consolidation Chemotherapy Among Patients With NSCLC Stage III Not Resectable
Status:
COMPLETED
Status Verified Date:
2016-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the best timing of the concomitant chemoradiotherapy among patients with NSCLC stage III not resectable treated by concomitant chemo-radiotherapy either preceded by a induction chemotherapy or followed by a consolidation chemotherapy
Detailed Description:
Chemotherapy
C Cisplatine 80 mgm² P Paclitaxel 200 mgm² N Vinorelbine 15 mgm²
Radiotherapy
66 Gy with 33 fractions 2 Gyfraction 1 fractionday 65 weeks High energy Photons X 9MV
C Cisplatine 80 mgm² P Paclitaxel 200 mgm² N Vinorelbine 15 mgm²
Radiotherapy
66 Gy with 33 fractions 2 Gyfraction 1 fractionday 65 weeks High energy Photons X 9MV
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None